MEI Pharma (MEIP), updated investors this morning on the phase 2 trial of Pracinostat / Vidaza combo for elderly patients with AML. The trial is about 50% complete, with a total of 14 patients currently evaluated. The update is positive with (8) or 57% of AML patients achieving a CR + CRi response...
This update came four months after the initial trial update that saw (3) or 33% of patients achieve a CR+CRi response. The mid trial results will be presented at the 2014 ASH (American Society of Hematology) conference December 6-9. Below is the abstract.
ASH 2014 Pracinostat
MEIP has two other phase 2 trials with Pracinostat / Vidaza for patients with MDS.
- Phase 2 study of Pracinostat and Vidaza in patients with previously untreated MDS, (enrollment complete).
- Phase 2 study of Pracinostat and Vidaza in patients who have failed to respond to single agent HMA.
Pracinostat has been generally well tolerated in over 300 patients to date.
MEI Pharma owns worldwide rights to Pracinostat, and has patent until 2028.
This update came four months after the initial trial update that saw (3) or 33% of patients achieve a CR+CRi response. The mid trial results will be presented at the 2014 ASH (American Society of Hematology) conference December 6-9. Below is the abstract.
ASH 2014 Pracinostat
MEIP has two other phase 2 trials with Pracinostat / Vidaza for patients with MDS.
- Phase 2 study of Pracinostat and Vidaza in patients with previously untreated MDS, (enrollment complete).
- Phase 2 study of Pracinostat and Vidaza in patients who have failed to respond to single agent HMA.
Pracinostat has been generally well tolerated in over 300 patients to date.
MEI Pharma owns worldwide rights to Pracinostat, and has patent until 2028.
Below is a weekly chart of MEI Pharma.
.png)
Source: Shaw Investments, StockCharts.com
Bottom Line: Pracinostat combo with Vidaza has shown nice potential for patients with AML and MDS, where there are few options available. The company has two MDS trials in progress, and plans to release those results in the first quarter of 2015. Sunesis has released some positive data for similar patients with AML. The important factor outside of safety will be how long the therapies last. Thank you for reading.
No comments:
Post a Comment